


# A Vaccine against Ebola Virus

Erica Ollmann Saphire

La Jolla Institute for Immunology, La Jolla, CA, USA

Correspondence: [erica@lji.org](mailto:erica@lji.org)

<https://dx.doi.org/10.1016/j.cell.2020.03.011>



**Ervebo is the first licensed vaccine for prevention of Ebola virus disease. The vaccine, originally developed by the Public Health Agency of Canada, is delivered in a single 1 mL dose and has been delivered to >200,000 people in an ongoing 2018–2020 outbreak of disease.**

**NAME**  
Ervebo

**APPROVED FOR**  
Prevention of Ebola virus disease in persons 18 years or older

**TYPE**  
A recombinant, live attenuated vaccine containing recombinant vesicular stomatitis virus (VSV) backbone in which the VSV envelope glycoprotein (GP) has been replaced with the envelope glycoprotein of Ebola virus.


**MOLECULAR TARGETS**  
The envelope glycoprotein of Ebola virus

**CELLULAR TARGETS**  
The vaccine induces production of antibodies against the envelope glycoprotein of Ebola virus.

**EFFECTS ON TARGETS**  
Antibodies bind to multiple known target sites on the Ebola virus surface glycoprotein. By binding, antibodies could mechanically neutralize or inactivate virions or could tag virions and infected cells for destruction and clearance by the immune system. T cells, particularly CD8+ T cells, against the Ebola virus glycoprotein are also elicited.

**DEVELOPED BY**  
Public Health Agency of Canada developed the original EBOV-rVSV vaccine assembly with commercial rights later licensed to NewLink Genetics Corp. Merck licensed the vaccine from NewLink in November 2014 to further develop, manufacture, and distribute it. *In vivo* efficacy and safety studies have been performed by multiple groups.



## Location and size of Ebola virus outbreak



## People vaccinated



## Antibody epitopes on Ebola virus GP



References for further reading is available with this article online: [www.cell.com/cell/S0092-8674\(20\)30263-4](http://www.cell.com/cell/S0092-8674(20)30263-4)

